Lewy bodies, composed in part of fibrillated α-synuclein,3 are present throughout the brain, often including much of the frontal cortex in later stages of the disease and in Parkinson’s disease dementia.4 Currently, no disease-modifying therapies are available for Parkinson’s disease or related Lewy body diseases, and so there is a strong need for therapeutics development. Here, SNCA is linked to Lewy body dementia.